Law360, New York (February 25, 2011, 2:31 PM ET) -- A drugmaker, a dermatology lab and New York University slapped Novartis AG unit Sandoz Inc. with a patent infringement suit Wednesday in Delaware over Sandoz's bid for regulatory approval to market a generic version of the rosacea treatment Oracea.
Supernus Pharmaceuticals Inc., Galderma Laboratories LP and NYU accuse Sandoz of infringing five patents, according to a complaint in the U.S. District Court for the District of Delaware. Galderma Laboratories Inc. and The Research Foundation of the State University of New York are also named as plaintiffs...
Sandoz Hit With Patent Suit Over Skin Condition Drug
To view the full article, take a free trial now.
